A Novel Genetic Mechanism of Caplacizumab Resistance in iTTP – JTH
Journal of Thrombosis and Haemostasis (JTH) shared a post on LinkedIn about a recent article by Mari Thomas et al., adding:
“Caplacizumab Resistance in Immune Thrombotic Thrombocytopenic Purpura (iTTP) Associated with VWF A1 Domain Missense Variant
This landmark first report describes caplacizumab resistance in an iTTP patient caused by a VWF A1 domain missense variant (P1266L) that impairs drug binding, revealing a novel genetic mechanism of treatment failure beyond premature therapy discontinuation.”
Title: Caplacizumab resistance in immune thrombotic thrombocytopenic purpura is associated with a von Willebrand factor A1 domain missense variant
Authors: Mari Thomas, Imogen Buckle, Adela Constantinescu-Bercu, Rens De Groot, Sabina McCann, Marie Scully
Read the Full Article on JTH
Other articles about Journal of Thrombosis and Haemostasis
-
Oct 15, 2026, 19:41Looking Beyond Platelet Counts to Quality of Life in ITP – American Society of Hematology
-
Oct 15, 2026, 19:32Markus Gregorio Barbosa: Hepatic VPS35 and Cholesterol Homeostasis
-
Oct 15, 2026, 19:18Emerging Novel Therapies for Hereditary Hemorrhagic Telangiectasia – The Lancet Haematology
-
Oct 15, 2026, 19:04Umberto Pensato: EVT Treatment Effects Across Perfusion Profiles in MeVO Stroke
-
Oct 15, 2026, 18:26Chanakya Nayudu: Presenting My Research at ISTH Congress 2026 in Paris
-
Oct 15, 2026, 18:09Maha Othman: Students Lead World Thrombosis Day 2026 Awareness Events
-
Oct 15, 2026, 17:52Jill de Mol։ Rapamycin Modulates Immune Responses in Aged Atherosclerosis
-
Oct 15, 2026, 17:41Victor Aboyans։ Think About Lipids in VTE
-
Oct 15, 2026, 17:08Babu Mia։ Targeting PPM1D to Eliminate Malignant Stem Cells in Myeloproliferative Neoplasms